Compare Hinge Health Inc. Class A Common Stock (HNGE) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs VanEck Rare Earth/Strategic Metals — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while VanEck Rare Earth/Strategic Metals trades at $56 (market cap $1.64B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 5.2× VanEck Rare Earth/Strategic Metals's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and VanEck Rare Earth/Strategic Metals for 52 Days on average.
| HNGE | REMX | |
|---|---|---|
Market Cap | $8.48B | $1.64B |
Volume | 879,799 | 710,568 |
Sector | Health | Sector/Thematic |
52-Week High | $105.14 | $109.53 |
52-Week Low | $31.17 | $55.78 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $8.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $57.45, down 1.25% amid bearish technical signals with moving averages indicating strong selling pressure. The ETF provides exposure to 38 global rare earth companies but faces high volatility and China concentration risks. Recent institutional activity includes Bank of America increasing its position by 72.1% in Q2 2026, while geopolitical developments around critical minerals supply chains continue to influence sentiment.
The outlook remains challenged by technical weakness and sector volatility, though oversold RSI readings suggest potential near-term bounce. Long-term prospects hinge on U.S. supply chain development and China export policies, but the ETF's 50% annualized volatility makes it unsuitable for conservative investors. Strategic importance of rare earths supports thematic interest despite execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
